Abbott Laboratories (NYSE:ABT) markets everything from Similac baby formula to cataract surgery equipment and its restructuring itself in order to spark revenue growth. 

Abbott is a long-standing member of the S&P 500 dividend aristocrats, a collection of companies with a proud history of dividend increases, so investors are right to wonder if sluggish sales tied to a recall last fall are ready to rebound.

Source: Abbott Labs

In the following slideshow, I include the most important takeaways from Abbott's second-quarter results and highlight the key reasons Abbott may find the second half of this year is better than the first.